文献速递膀胱癌与上尿路尿路上皮癌

肌层浸润性膀胱癌治疗选择:患者偏好研究

Muscle-Invasive Bladder Cancer Treatment Selection in an Emerging Treatment Era: A Patient Preference Study.
PubMed 文献 · Urology · 2025-08-12

结果显示患者最看重5年总生存期改善和延缓复发,并愿为此耐受治疗相关不良事件;约75%选择围手术期免疫治疗联合新辅助化疗加根治性膀胱切除术。

要点

  • 患者最重视5年总生存期改善,其次为延缓癌症复发时间。
  • 患者愿为疗效提升耐受假设性不良事件及递增风险。
  • 约75%受访者选择围手术期免疫联合新辅助化疗加根治性膀胱切除术。

核心结论

  • 改善总生存期和延缓复发是受访者最重要的治疗属性,患者愿为疗效提升接受临床相关不良事件。

研究设计与样本

  • 评估系统治疗属性包括治疗时机与持续时间、至癌症复发时间、5年总生存期及治疗相关不良事件概率。
  • 采用SDM-Q-9问卷评估患者对治疗的满意度。

主要发现

  • 疗效改善最重要,其中5年总生存期优先于至癌症复发时间。
  • 平均患者对假设性不良事件耐受,并愿为所有总生存期改善接受递增风险水平。
  • 在固定选择问题中约75%受访者选择围手术期免疫治疗联合新辅助化疗加根治性膀胱切除术,而非单纯新辅助化疗加根治性膀胱切除术。
  • SDM-Q-9中近20%受访者不同意「我的医生询问过我偏好哪种治疗方案」。

临床怎么用

  • 结果可用于患者教育和促进共享治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To elicit preferences for available and emerging systemic treatments among patients with muscle-invasive bladder cancer in the United States. MATERIALS AND METHODS: Patients with self-reported muscle-invasive bladder cancer participated in an online discrete-choice experiment evaluating preferences for attributes of systemic treatments that could be administered with radical cystectomy or bladder-sparing approaches. Evidence-based attributes included timing and duration of therapy, time until cancer recurrence, overall survival at 5 years, and chance of treatment-related adverse events. Direct-elicitation questions offered choices among fixed profiles of bladder-sparing treatment and radical cystectomy with adjuvant and neoadjuvant systemic treatments. The 9-item Shared Decision Making Satisfaction Questionnaire (SDM-Q-9) captured patients' levels of satisfaction with treatment. RESULTS: Two hundred two respondents completed the survey. Most patients preferred to keep their bladder. Improvements in efficacy were most important (overall survival at 5 years, followed by the time until cancer recurrence). The average patient was tolerant of hypothetical adverse events and willing to accept increasing levels of risk for all overall survival improvements offered. Approximately 75% of respondents chose perioperative immunotherapy plus neoadjuvant chemotherapy with radical cystectomy over neoadjuvant chemotherapy alone with radical cystectomy in a fixed-choice question. On the SDM-Q-9, almost 20% of respondents disagreed with the statement "My doctor asked me which treatment option I prefer." CONCLUSION: Improving overall survival and delaying recurrence were the most important attributes to respondents, and they were willing to accept clinically relevant treatment-related adverse events for improvements in efficacy. Results may inform patient education and engagement in shared treatment decisions.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Smith AB, Gore JL, Chisolm S, et al. Muscle-Invasive Bladder Cancer Treatment Selection in an Emerging Treatment Era: A Patient Preference Study. Urology. 2025. PMID: 40812591. doi:10.1016/j.urology.2025.08.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。